Shots:
- Trial assessed enlicitide (QD, PO) vs non-statin therapies (PO) added to background statins in adults with hypercholesterolemia & ASCVD risk or history, meeting its 1EP with a 64.6% LDL-C reduction at 8wks. & reductions of 56.7% vs bempedoic acid, 36% vs ezetimibe, & 28.1% vs their combination
- Trial also showed 8wk. reductions in ApoB (−54.6%) vs bempedoic acid (−5.4%), ezetimibe (−20.2%) & combination (−27.7%), along with non-HDL-C (−58%) vs −5.2%, −25.1% & −31.8%
- Enlicitide also reduced Lp(a) by 26.2% vs +8.1%, 0% & +10.4%, & enabled 78.2% to achieve ≥50% LDL-C reduction with levels <55 mg/dL vs 2%, 8% & 20%; data were presented at ACC’26 & simultaneously published in JACC
Ref: Merck | Image: Merck | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
